pSG5LHARB1sgresistant
(Plasmid
#229856)
-
PurposeRB1
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 229856 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepSG5L
-
Backbone manufacturer4000
- Backbone size w/o insert (bp) 2800
-
Modifications to backboneThe RB1 was originally cloned by Dr. William Sellers (Plasmid #10720).
-
Vector typeMammalian Expression
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert 1
-
Gene/Insert nameRB1
-
SpeciesH. sapiens (human)
-
Mutationchanged a bp24 to g; g bp27 to c, and c bp30 to g. These are silenced mutations.
-
Entrez GeneRB1 (a.k.a. OSRC, PPP1R130, RB, p105-Rb, p110-RB1, pRb, pp110)
-
Tag
/ Fusion Protein
- HA (N terminal on backbone)
Cloning Information for Gene/Insert 1
- Cloning method Restriction Enzyme
- 5′ cloning site BamHI (not destroyed)
- 3′ cloning site EcoRI (not destroyed)
- 5′ sequencing primer T7 (Common Sequencing Primers)
Gene/Insert 2
-
Gene/Insert nameRb1
-
Alt nameOSRC, PPP1R130, RB, p105-Rb, p110-RB1, pRb, pp110
-
SpeciesH. sapiens (human)
-
Entrez GeneRB1 (a.k.a. OSRC, PPP1R130, RB, p105-Rb, p110-RB1, pRb, pp110)
Resource Information
-
A portion of this plasmid was derived from a plasmid made byWilliam Sellers originally cloned this gene (Plasmid #10720).
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pSG5LHARB1sgresistant was a gift from Maria Alvarado-Kristensson (Addgene plasmid # 229856 ; http://n2t.net/addgene:229856 ; RRID:Addgene_229856) -
For your References section:
Targeting TUBG1 in RB1-negative tumors. Lindstrom L, Zhou J, Villoutreix BO, Malycheva D, Otrocka M, Gustavsson AL, Lundback T, Bliman D, Shameem MA, Straw M, Riesbeck K, Olsson R, Alvarado-Kristensson M. FASEB J. 2025 Mar 15;39(5):e70431. doi: 10.1096/fj.202403180RR. 10.1096/fj.202403180RR PubMed 40019206